組織蛋白酶D(CTSD)活性蛋白
Active Cathepsin D (CTSD)
CPSD; CLN10; Lysosomal Aspartyl Protease; Ceroid-Lipofuscinosis,Neuronal 10
- 編號APB280Hu61
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 緩沖液成份磷酸鹽緩沖液(pH7.4,含有 0.01% SKL, 1mM DTT, 5% Trehalose和Proclin300.)
- 性狀凍干粉
- 純度> 97%
- 等電點(diǎn)6.1
- 應(yīng)用Cell?culture;?Activity?Assays.
- 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 ¥ 2016 ¥ 5040 ¥ 10080 ¥ 30240 ¥ 75600
- 欲了解實(shí)際交易價(jià)格和更多情況,請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
活性實(shí)驗(yàn)
Figure. The binding activity of CTSD with HSP90b1.
Cathepsin D (CSTD) is an aspartic protease that depends critically on protonation of its active site Asp residue. Along with Asp-protonation, lower pH also leads to conformational switch in cathepsin-D: the N-terminal segment of the protease moves out of the active site as pH drops. Similar to other aspartic protainases, cathepsin D accommodates up to 8 amino acid residues in the binding cleft of the active site. The main physiological functions of cathepsin D consist of metabolic degradation of intracellular proteins, activation and degradation of polypeptide hormones and growth factors, activation of enzymatic precursors, processing of enzyme activators and inhibitors, brain antigen processing and regulation of programmed cell death. Besides, Heat Shock Protein 90kDa Beta 1 (HSP90b1) has been identified as an interactor of CSTD, thus a binding ELISA assay was conducted to detect the interaction of recombinant human CSTD and recombinant human HSP90b1. Briefly, CSTD were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100μL were then transferred to HSP90b1-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h with anti-CSTD pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50μL stop solution to the wells and read at 450nm immediately. The binding activity of CSTD and HSP90b1 was shown in Figure 1, and this effect was in a dose dependent manner.
用法
Reconstitute in 20mM Tris, 150mM NaCl (PH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復(fù)凍融。2-8°C不超過一個(gè)月,-80°C不超過12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時(shí),沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲,損失率低于5%。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
編號 | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
APB280Hu61 | 組織蛋白酶D(CTSD)活性蛋白 | Cell?culture;?Activity?Assays. |
EPB280Hu61 | 組織蛋白酶D(CTSD)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPB280Hu01 | 組織蛋白酶D(CTSD)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APB280Hu62 | 組織蛋白酶D(CTSD)活性蛋白 | Cell?culture;?Activity?Assays. |
EPB280Hu62 | 組織蛋白酶D(CTSD)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPB280Hu02 | 組織蛋白酶D(CTSD)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPB280Hu03 | 組織蛋白酶D(CTSD)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPB280Hu04 | 組織蛋白酶D(CTSD)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAB280Hu02 | 組織蛋白酶D(CTSD)多克隆抗體 | WB; IHC; ICC; IP. |
PAB280Hu01 | 組織蛋白酶D(CTSD)多克隆抗體 | WB; IHC; ICC; IP. |
LAB280Hu71 | 組織蛋白酶D(CTSD)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
MAB280Hu21 | 組織蛋白酶D(CTSD)單克隆抗體 | WB; IHC; ICC; IP. |
MAB280Hu26 | 組織蛋白酶D(CTSD)單克隆抗體 | WB; IHC; ICC; IP. |
MAB280Hu22 | 組織蛋白酶D(CTSD)單克隆抗體 | WB; IHC; ICC; IP. |
FAB280Hu02 | 抗組織蛋白酶D(CTSD)單克隆抗體 | Flow cytometry. |
SEB280Hu | 組織蛋白酶D(CTSD)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
HEB280Hu | 組織蛋白酶D(CTSD)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,高敏型) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMB280Hu | 組織蛋白酶D(CTSD)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Molecular Immunology | Cathepsin D is released after severe tissue trauma in vivo and is capable of generating C5a in vitro [ScienceDirect: S0161589011008297] |
21 | Plasma Cathepsin D Levels: A Novel Tool to Predict Pediatric Hepatic Inflammation [PubMed: 25732418] |
Scientific Reportes | Plasma cathepsin D correlates with histological classifications of fatty liver disease in adults and responds to intervention [pubmed:27922112] |
Biomedicine & pharmacotherapy | Berberine ameliorates intrahippocampal kainate-induced status epilepticus and consequent epileptogenic process in the rat: Underlying mechanisms [pubmed:28061403] |
JGH OPEN | Limited applicability of cathepsin D for the diagnosis and monitoring of non‐alcoholic steatohepatitis [] |
Diabetologia | Plasma cathepsin D activity is negatively associated with hepatic insulin sensitivity in overweight and obese humans [Pubmed: 31690989] |
Antioxidants | Iron and Advanced Glycation End Products: Emerging Role of Iron in Androgen Deficiency in Obesity [Pubmed: 32235809] |
Peptides | LVV-hemorphin-7 (LVV-H7) plays a role in antinociception in a rat model of alcohol-induced pain disorders [33253777] |
Cells | Identification of Cathepsin D as a Plasma Biomarker for Alzheimer's Disease [33445607] |
J Chem Neuroanat | Analysis of silymarin-modulating effects against acrylamide-induced cerebellar damage in male rats: Biochemical and pathological markers [33965515] |
Front Cell Infect Microbiol | PGRS Domain of Rv0297 of Mycobacterium tuberculosis Is Involved in Modulation of Macrophage Functions to Favor Bacterial Persistence [33042856] |
Nutr Metab Cardiovasc Dis | Serum CathepsinD in pregnancy: relation with metabolic and inflammatory markers and effects of fish oils and probiotics [Pubmed:35304048] |
Biosensors | A Comparison of Various Chips Used for the Manufacture of Biosensors Applied in Non-Fluidic Array SPRi, Based on the Example of Determination of Cathepsin D [Pubmed:35049649] |